CA2560508A1 - Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation - Google Patents

Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation Download PDF

Info

Publication number
CA2560508A1
CA2560508A1 CA002560508A CA2560508A CA2560508A1 CA 2560508 A1 CA2560508 A1 CA 2560508A1 CA 002560508 A CA002560508 A CA 002560508A CA 2560508 A CA2560508 A CA 2560508A CA 2560508 A1 CA2560508 A1 CA 2560508A1
Authority
CA
Canada
Prior art keywords
cancer
antibody
beta
alpha
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002560508A
Other languages
English (en)
French (fr)
Inventor
Vanitha Ramakrishnan
Vinay Bhaskar
Sun Ho
Richard Murray
Debbie Law
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Biotherapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2560508A1 publication Critical patent/CA2560508A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA002560508A 2004-03-24 2005-03-24 Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation Abandoned CA2560508A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US55642204P 2004-03-24 2004-03-24
US55642104P 2004-03-24 2004-03-24
US60/556,421 2004-03-24
US60/556,422 2004-03-24
US62504904P 2004-11-03 2004-11-03
US60/625,049 2004-11-03
US65109805P 2005-02-07 2005-02-07
US60/651,098 2005-02-07
US65751405P 2005-02-28 2005-02-28
US60/657,514 2005-02-28
PCT/US2005/009939 WO2005092073A2 (en) 2004-03-24 2005-03-24 Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation

Publications (1)

Publication Number Publication Date
CA2560508A1 true CA2560508A1 (en) 2005-10-06

Family

ID=35056776

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002560508A Abandoned CA2560508A1 (en) 2004-03-24 2005-03-24 Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation

Country Status (14)

Country Link
US (2) US7662384B2 (https=)
EP (1) EP1755659B1 (https=)
JP (1) JP4857259B2 (https=)
KR (1) KR20070009637A (https=)
AT (1) ATE531388T1 (https=)
AU (1) AU2005226736B2 (https=)
BR (1) BRPI0509177A (https=)
CA (1) CA2560508A1 (https=)
DK (1) DK1755659T3 (https=)
ES (1) ES2376556T3 (https=)
IL (1) IL178042A (https=)
NO (1) NO20064794L (https=)
NZ (1) NZ549893A (https=)
WO (1) WO2005092073A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3167888T3 (pl) 2006-03-15 2024-08-26 Alexion Pharmaceuticals, Inc. Leczenie pacjentów z napadową nocną hemoglobinurią za pomocą inhibitora dopełniacza
HRP20150884T1 (hr) * 2006-03-21 2015-09-25 Genentech, Inc. Kombinacijska terapija koja ukljuäśuje antagoniste alfa5beta1
WO2007114851A1 (en) * 2006-04-04 2007-10-11 The Board Of Trustees Of The University Of Illinois Methods and compositions to induce cell death of invasive tumors
CA2652886A1 (en) * 2006-05-24 2007-11-29 Bayer Schering Pharma Aktiengesellschaft High affinity human and humanized anti-.alpha.5.beta.1 integrin function blocking antibodies with reduced immunogenicity
WO2008061377A1 (en) * 2006-11-22 2008-05-29 Centre Hospitalier De L'universite De Montreal Novel receptor for cd40l and uses thereof
AU2008282331A1 (en) * 2007-07-27 2009-02-05 Facet Biotech Corporation Pharmaceutical combinations comprising a tyrosine kinase inhibitor and an antibody against integrin alpha 1 beta 5 (CD49E)
CL2008002856A1 (es) * 2007-09-26 2009-01-16 Genentech Inc Anticuerpo novedoso (anticuerpo anti-integrina a5b1; mol}ecula de ácido nucleico que lo codifica; vector y célula huesped; método de producción; composición farmacéutica que lo comprende; su uso para inhibir la angiogénesis y/o permeabilidad vascular y cáncer entre otras patologías; y método de detección de la integrina a5b1).
NZ587440A (en) 2008-02-05 2013-01-25 Pfizer Antibodies specific for human integrin alpha 5 - beta 1 and their uses for treating tumours
WO2010072740A2 (en) 2008-12-23 2010-07-01 Astrazeneca Ab TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
MY173526A (en) * 2009-03-25 2020-01-31 Genentech Inc Novel anti-?5?1 antibodies and uses thereof
US20110319335A1 (en) 2010-06-23 2011-12-29 Xiaodong Feng Combined administration of integrin receptor antagonists for anti-angiogenic therapy
SG10201604104PA (en) 2011-10-25 2016-07-28 Prothena Therapeutics Ltd Antibody formulations and methods
US8946159B2 (en) * 2011-12-22 2015-02-03 California Northstate College Of Pharmacy, Llc Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment
NO2760138T3 (https=) 2012-10-01 2018-08-04
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
AU2018263868A1 (en) 2017-05-02 2019-12-12 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
KR102885113B1 (ko) 2018-10-18 2025-11-13 머크 샤프 앤드 돔 엘엘씨 항-rsv 항체의 제제 및 그의 사용 방법
CN120842406A (zh) 2018-10-31 2025-10-28 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
CN113316458B (zh) 2018-11-07 2024-08-02 默沙东有限责任公司 抗lag3抗体和抗pd-1抗体的共制剂
WO2025106724A2 (en) * 2023-11-15 2025-05-22 Morphic Therapeutic, Inc. USE OF ANTI-α5β1 ANTIBODIES IN THE TREATMENT OF PULMONARY HYPERTENSION AND HEART FAILURE
TW202540178A (zh) * 2023-11-15 2025-10-16 美商莫菲克醫療股份有限公司 人類抗－α５β１抗體及其用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704366A (en) 1984-06-22 1987-11-03 Bio-Rad Laboratories, Inc. Process for binding IgG to protein A
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0531472B1 (en) 1991-03-06 2003-08-13 MERCK PATENT GmbH Humanized monoclonal antibodies
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
ATE171472T1 (de) 1992-02-19 1998-10-15 Schering Corp Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
JP3490443B2 (ja) 1992-10-29 2004-01-26 ジ・オーストラリアン・ナショナル・ユニバーシティ 血管形成阻害性抗体
US5536814A (en) 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
WO1995022618A1 (en) 1994-02-22 1995-08-24 Dana-Farber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
DE69516351T2 (de) * 1994-09-21 2000-12-07 Matsushita Electric Industrial Co., Ltd. Sekundäre Lithium Feststoffbatterie
US5705154A (en) 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
JP2001527513A (ja) 1996-03-15 2001-12-25 デュポン ファーマシューティカルズ カンパニー スピロ環インテグリン阻害剤
US5922676A (en) 1996-09-20 1999-07-13 The Burnham Institute Methods of inhibiting cancer by using superfibronectin
US5846536A (en) 1996-10-04 1998-12-08 The Regents Of The University Of California Restoration of normal phenotype in cancer cells
WO1998032771A1 (en) 1997-01-29 1998-07-30 Toray Industries, Inc. Chimeric proteins, heterodimer complexes thereof and substitute for platelet
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AU2444899A (en) * 1998-01-22 1999-08-09 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
US6495319B1 (en) 1998-04-27 2002-12-17 Sidney Kimmel Cancer Center Reduced complexity nucleic acid targets and methods of using same
US6852318B1 (en) 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
CA2328414C (en) * 1998-05-08 2014-04-15 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
EP1204764A2 (en) 1999-08-11 2002-05-15 EOS Biotechnology, Inc. Methods of screening for angiogenesis modulators
CA2397194C (en) 2000-01-20 2011-05-17 Mark E. Duggan Alpha v integrin receptor antagonists
EP1254116A4 (en) 2000-01-24 2003-04-23 Merck & Co Inc ALPHA V INTEGRIN RECEPTOR ANTAGONISTS
US7740841B1 (en) * 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
US20040259152A1 (en) 2000-02-22 2004-12-23 Richard Murray Novel methods of diagnosing and screening for modulators of tissue remodeling and treating related diseases
WO2002079492A2 (en) 2001-02-14 2002-10-10 Protein Design Labs, Inc. Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
US7276589B2 (en) 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
KR20110140143A (ko) * 2002-11-26 2011-12-30 애보트 바이오테라퓨틱스 코포레이션 혈관형성을 조절하는 α5β1 인테그린에 대한 키메라성 및 인간화 항체
EP1625165A2 (en) * 2003-04-03 2006-02-15 Protein Design Labs, Inc. Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation
KR101424624B1 (ko) 2003-05-14 2014-07-31 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물

Also Published As

Publication number Publication date
JP4857259B2 (ja) 2012-01-18
EP1755659A2 (en) 2007-02-28
US20050260210A1 (en) 2005-11-24
NZ549893A (en) 2010-05-28
ATE531388T1 (de) 2011-11-15
EP1755659A4 (en) 2008-08-20
DK1755659T3 (da) 2012-02-27
HK1101348A1 (en) 2007-10-18
AU2005226736B2 (en) 2009-11-26
JP2007530584A (ja) 2007-11-01
WO2005092073A3 (en) 2006-08-10
ES2376556T3 (es) 2012-03-14
KR20070009637A (ko) 2007-01-18
BRPI0509177A (pt) 2007-09-18
AU2005226736A1 (en) 2005-10-06
US7662384B2 (en) 2010-02-16
WO2005092073A2 (en) 2005-10-06
IL178042A (en) 2011-05-31
NO20064794L (no) 2006-10-23
EP1755659B1 (en) 2011-11-02
IL178042A0 (en) 2006-12-31
US20100291111A1 (en) 2010-11-18

Similar Documents

Publication Publication Date Title
US20100291111A1 (en) Use of Anti-Alpha5Beta1 Antibodies to Inhibit Cancer Cell Proliferation
US12528865B2 (en) Treatment of lung cancer using a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody
US20200046832A1 (en) Compositions comprising anti-cd38 antibodies and lenalidomide
KR20180081606A (ko) 암 치료에서의 단독의, 또는 면역 자극제와 병용한, fgfr2 억제제
EP3836950A1 (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
EP4101464A1 (en) Use of anti-pd-1 antibody in treatment of malignant tumors
CN1933851B (zh) 使用抗-α5β1抗体抑制癌细胞增殖
CN118557748A (zh) 使用抗cd123免疫缀合物的治疗方法
RU2361614C2 (ru) ПРИМЕНЕНИЕ АНТИТЕЛ ПРОТИВ α5β1 ДЛЯ ИНГИБИРОВАНИЯ ПРОЛИФЕРАЦИИ РАКОВЫХ КЛЕТОК
KR20240149434A (ko) 암을 치료하기 위한 체크포인트 저해제 및 종양용해 바이러스의 조합
JP2025521028A (ja) 併用療法
HK1101348B (en) Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
KR20250148463A (ko) 담도암의 치료를 위한 항-her2/항-4-1bb 이중 특이 항체
KR20260054704A (ko) 항-pd-1 및 화학요법을 이용한 폐암 치료
KR20240099363A (ko) 항-pd-1 항체와 항-cd30 항체-약물 접합체의 조합을 사용하여 암을 치료하는 방법
EP4615871A1 (en) Anti carcinoembryonic antigen-related cell adhesion molecule 1 (ceacam1) antibodies for inhibition of neutrophil extracellular traps (net)-mediated activities
CN115607662A (zh) 抗pd-1抗体在治疗腺泡状软组织肉瘤中的应用

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20150123